• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

    34.64 +2.09 (+6.42%)
    Streaming Delayed Price Updated: 2:21 PM EST, Jan 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 506,868
    Open 32.22
    Bid (Size) 34.59 (100)
    Ask (Size) 34.69 (900)
    Prev. Close 32.55
    Today's Range 32.22 - 34.74
    52wk Range 5.350 - 38.69
    Shares Outstanding 44,188,534
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? ↗
    This biotech targeting rare genetic diseases reported a notable insider sale following a year of rapid share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance

    Performance

    YTD
    +12.1%
    +12.1%
    1 Month
    +5.0%
    +5.0%
    3 Month
    +29.2%
    +29.2%
    6 Month
    +196.3%
    +196.3%
    1 Year
    +214.3%
    +214.3%

    More News

    Read More
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
    Via Benzinga
    News headline image
    Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    6 Analysts Have This To Say About Stoke Therapeutics ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Examining the Future: Stoke Therapeutics's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    What 4 Analyst Ratings Have To Say About Stoke Therapeutics ↗
    Via Benzinga
    News headline image
    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
    From Stoke Therapeutics, Inc.
    Via Business Wire
    News headline image
    Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
    From Biogen Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Stoke Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Stoke Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Stoke Therapeutics, Inc. - Common Stock trade on?
    Stoke Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Stoke Therapeutics, Inc. - Common Stock?
    The ticker symbol for Stoke Therapeutics, Inc. - Common Stock is STOK on the Nasdaq Stock Market
    What is the current price of Stoke Therapeutics, Inc. - Common Stock?
    The current price of Stoke Therapeutics, Inc. - Common Stock is 34.64
    When was Stoke Therapeutics, Inc. - Common Stock last traded?
    The last trade of Stoke Therapeutics, Inc. - Common Stock was at 01/06/26 02:21 PM ET
    What is the market capitalization of Stoke Therapeutics, Inc. - Common Stock?
    The market capitalization of Stoke Therapeutics, Inc. - Common Stock is 1.53B
    How many shares of Stoke Therapeutics, Inc. - Common Stock are outstanding?
    Stoke Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.